Stockscreener 앱 받기
5.26
1.74%
0.09
시장 영업 전:
5.26
Aldeyra Therapeutics Inc 주식(ALDX)의 최신 뉴스
Aldeyra price target raised to $9 from $6 at Jones Trading on FDA acceptance - Investing.com Canada
Aldeyra Therapeutics to Participate in the H.C. Wainwright 5th A - GuruFocus
Aldeyra CEO to Share Exclusive Ophthalmology Pipeline Updates at H.C. Wainwright Conference - Stock Titan
Why is Aldeyra Therapeutics Inc. stock attracting strong analyst attentionTremendous portfolio expansion - Jammu Links News
Is Aldeyra Therapeutics Inc. a good long term investmentBuild a portfolio that outperforms the market - Jammu Links News
What makes Aldeyra Therapeutics Inc. stock price move sharplyFree Trend-Following Techniques - Jammu Links News
How does Aldeyra Therapeutics Inc. generate profit in a changing economyPowerful profit generation - Jammu Links News
Should I hold or sell Aldeyra Therapeutics Inc. stock in 2025Strongest growth potential - Jammu Links News
When is Aldeyra Therapeutics Inc. stock expected to show significant growthSky-high profits - Jammu Links News
Published on: 2025-08-02 20:17:22 - beatles.ru
Is Aldeyra Therapeutics Inc. stock overvalued or undervaluedEarnings Report Alerts With Proven Results - Jammu Links News
What are analysts’ price targets for Aldeyra Therapeutics Inc. in the next 12 monthsWealth Building Insights That Work - Jammu Links News
How many analysts rate Aldeyra Therapeutics Inc. as a “Buy”AI Powered Entry Points That Work - Jammu Links News
Exploring US High Growth Tech Stocks For July 2025 - simplywall.st
Why Aldeyra Therapeutics Inc. stock attracts strong analyst attentionConsistent Gain Investment Strategies Emerge - metal.it
Published on: 2025-07-29 20:51:08 - metal.it
Trendline Breach Raises Concern for Aldeyra Therapeutics Inc. InvestorsCommunity Verified Stock Suggestions Drive Volume - metal.it
Why did ALDX's EPS remain stagnant in recent quarters? - AInvest
How Aldeyra Therapeutics Inc. stock performs during market volatilityFundamental Growth Stock Analysis Shows Strength - metal.it
How volatile is Aldeyra Therapeutics Inc. stock compared to the marketUnmatched market performance - Jammu Links News
What makes Aldeyra Therapeutics Inc. stock attractive to long term investorsAnalyst Grade Signals - metal.it
What is the risk reward ratio of investing in Aldeyra Therapeutics Inc. stockCapitalize on strategic market trends - Jammu Links News
What are Aldeyra Therapeutics Inc. company’s key revenue driversUnlock high-yield investment opportunities - jammulinksnews.com
Aldeyra Therapeutics receives orphan designation for ADX-2191 from EMA - Ophthalmology Times
Aldeyra Therapeutics Receives Orphan Designation from the Europe - GuruFocus
What drives Aldeyra Therapeutics Inc. stock priceFree Risk Assessment Services - printweek.in
What analysts say about Aldeyra Therapeutics Inc. stockExceptional gains - Autocar Professional
EMA grants orphan designation to ADX-2191 (Aldeyra Therapeutics) for inherited retinal dystrophies - Ophthalmology Times Europe
EMA grants orphan designation for Aldeyra’s eye treatment By Investing.com - Investing.com India
EMA grants orphan designation for Aldeyra’s eye treatment - Investing.com
Breakthrough: Aldeyra's Eye Drug Gets EU Orphan Status for Treating Incurable Genetic Blindness - Stock Titan
Published on: 2025-07-23 18:29:07 - Autocar Professional
Aldeyra Therapeutics Inc. Stock Analysis and ForecastSuperior returns - jammulinksnews.com
0.24%
3.39%
자본화:
|
볼륨(24시간):